Press Release Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update Aug 4
Press Release Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma Jul 29